Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors
By Nicole Longo | March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...
Read More
Look at the facts. Drug importation is dangerous.
By Nicole Longo | February 22, 2019
Today, 1 in 10 medicines worldwide and up to 50 percent of drugs consumed in developing nations are counterfeit. Importation proposals would open the U.S. borders to these dangerous and...
Read More
ICYMI: New study reinforces dangers of proposed IPI model
By Nicole Longo | January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...
Read More
PhRMA comments to administration on International Pricing Index Model
By Nicole Longo | January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...
Read More
ICYMI: WSJ and NYT highlight concerns with Part B International Pricing Index Model
By Nicole Longo | December 19, 2018
Medicare Part B is a market-based system that has enabled millions of seniors and patients with disabilities to access needed medicines. Reimbursement for medicines in Part B is based on the ...
Read More
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
By Nicole Longo | December 18, 2018
Data and analyses continue to show the 340B program influences prescribing trends at 340B hospitals – ultimately costing patients and our health care system more money. The Government...
Read More
Groups sound the alarm on administration’s new Part B proposal
By Nicole Longo | November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...
Read More
4 things you need to know about the administration’s latest Part B proposal
By Nicole Longo | November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....
Read More
ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
By Nicole Longo | October 9, 2018
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses, detailing how such schemes expose Americans to dangerous counterfeit medicines. The reporter...
Read More
PhRMA comments in response to request for information on competitive bidding program in Medicare Part B
By Nicole Longo | September 25, 2018
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule,...
Read More
Medicare Monday (100)
340B Spotlight (39)
Cost & Consequence (0)
